Shopping Cart 0
Cart Subtotal
USD 0

eTheRNA Immunotherapies NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

ETheRNA Immunotherapies NV (eTheRNA) is a developer of novel immunotherapies for the treatment of cancers and infectious diseases. The company's pipeline products include mRNA-based immunotherapies for various indications such as melanoma, triple negative breast cancer and infectious diseases. It provides preclinical and clinical proof to support further development of TriMix technology. eTheRNA also develops drugs for infectious diseases such as influenza, pneumonia, tuberculosis, Lyme disease, HIV and AIDS et cetera. The company also provides contract manufacturing services. It has collaborative partnerships with pharma companies for its research operations. eTheRNA is headquartered in Antwerp, Belgium.

eTheRNA Immunotherapies NV-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

eTheRNA Raises USD27 Million in Series A Financing 10

Partnerships 12

Mymetics Enters into Research Collaboration Agreement with eTheRNA 12

PCI Biotech Enters Research Agreement with eTheRNA immunotherapies 13

Licensing Agreements 14

eTheRNA Enters into Licensing Agreement with Vrije Universiteit Brussel 14

eTheRNA Immunotherapies NV-Key Competitors 15

eTheRNA Immunotherapies NV-Key Employees 16

eTheRNA Immunotherapies NV-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Recent Developments 18

Government and Public Interest 18

Sep 25, 2017: eTheRNA immunotherapies Awarded EUR1 Million Grant From Flanders Innovation & Entrepreneurship to Further Upgrade its State-of-the-art Production Process for TriMix mRNA Immunotherapies 18

Clinical Trials 19

Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma 19

Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies 20

Appendix 21

Methodology 21

About GlobalData 21

Contact Us 21

Disclaimer 21


List Of Figure

List of Figures

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Key Facts 2

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

eTheRNA Immunotherapies NV, Deals By Therapy Area, 2012 to YTD 2018 8

eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

eTheRNA Raises USD27 Million in Series A Financing 10

Mymetics Enters into Research Collaboration Agreement with eTheRNA 12

PCI Biotech Enters Research Agreement with eTheRNA immunotherapies 13

eTheRNA Enters into Licensing Agreement with Vrije Universiteit Brussel 14

eTheRNA Immunotherapies NV, Key Competitors 15

eTheRNA Immunotherapies NV, Key Employees 16

eTheRNA Immunotherapies NV, Other Locations 17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

eTheRNA Immunotherapies NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.